Click Here For COVID-19 (Coronavirus) Studies

Trials Offered by a Specific Doctor

Andrew Lassman, MD
(212) 342-0571

Andrew B. Lassman, MD, is the John Harris Associate Professor of Neurology and the Chief of Neuro-oncology at Columbia University. After earning BS and MS degrees in Molecular Biophysics and Biochemistry as part of a combined 4-year program at Yale University, he received his MD from Columbia University College of Physicians and Surgeons. Dr. Lassman subsequently completed his residency at the Neurological Institute of NewYork-Presbyterian Hospital/Columbia University Medical Center, and fellowship in Neuro-Oncology at Memorial Sloan-Kettering Cancer Center, where he then joined the faculty and served as fellowship director.

In November 2011, Dr. Lassman became Chief of Neuro-Oncology at Columbia University Medical Center, and also serves as the Medical Director for the Clinical Protocol Data Management Office of the Herbert Irving Comprehensive Cancer Center.

Dr. Lassman received the Preuss Award in Neuro-Oncology from the American Academy of Neurology, the Boyer Clinical Research Award from Memorial Sloan-Kettering Cancer Center, and the Gary Lichtenstein Humanitarian Award from Voices Against Brain Cancer. His clinical practice is limited to central nervous system tumors and metastases.

Clinical Studies Managed By Dr. Lassman:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for patients with newly-diagnosed Glioblastoma Multiforme using study drug BortezomibJonsson Comprehensive Cancer CenterAAAL6001
Details[CLOSED] A study for patients with HER2 positive breast cancer using study drug Trastuzumab for treatmentNorthwestern UniversityAAAO4157
Details[CLOSED] A study for patients with glioblastoma using study drug ABT-414AbbVieAAAQ2302
DetailsA study for patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide ChemotherapyOrbus TherapeuticsAAAQ9886
Details[CLOSED] A study for patients with malignant glioblastoma or glioma using study drug PF-06840003PfizerAAAR0112
Details[CLOSED] A study for patients with Glioblastoma using study drug Tesevatinib monotherapyKadmon Corporation, LLCAAAR1035
Details[CLOSED] Study of the efficacy and safety of Selinexor (KPT-330) in patients with recurrent gliomasNPM Pharma LTDAAAM6851
Details[CLOSED] Study of Radiotherapy with Adjuvant Drug versus Radiotherapy with PCV Chemotherapy in Patients with GliomaNCI AllianceAAAR0376
Details[CLOSED] Study of Treatment Effects in Subjects with Glioblastoma Multiforme (GBM) - Glioma, Brain TumorAbbVieAAAR1373
DetailsStudy of Vaccine for Cytomegalovirus (CMV) in Patients with Brain TumorVBI Vaccines, Inc.AAAR5300
Details[CLOSED] Study of Drug BGB-290 in Patients with GlioblastomaBeiGene, Ltd.AAAR6842
Details[CLOSED] Study for Management of Eye Side Effects in Patients with EGFR-Amplified Glioblastoma Receiving ABT-414AbbVieAAAR7433
Details[CLOSED] REGAL- Recurrent Glioblastoma Treated with Selinexor and TemozolomideKaryopharm, Inc.AAAR7797
DetailsStudy of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic ImagingNAAAAS0279
DetailsONC201 in Adults With Recurrent H3 K27M-mutant GliomaOncoceutics, Inc.AAAS1885
DetailsStudy of ABBV-321 in Subjects with Advanced Solid Tumors Associated with Overexpression of Epidermal Growth Factor Receptor (EGFR)AbbVieAAAS3006
DetailsA Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)Global Coalition for Adaptive ResearchAAAS2589
DetailsStudy of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma (type of brain cancer) With an IDH1 or IDH2 Mutation (INDIGO)Agios Pharmaceuticals, INC.AAAS8970